FDA Approves First Respiratory Syncytial Virus Vaccine for Adults Aged 60 Years and Older
May 3rd 2023Arexvy is the first respiratory syncytial virus (RSV) vaccine approved in the United States for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age and older.
Read More
Expert: Pharmacy, Medical Benefit Adoption of Biosimilars Present Different Challenges
May 2nd 2023Fran Gregory, PharmD, MBA, vice president of Emerging Therapies at Cardinal Health, discussed the biosimilars landscape and where biosimilars fall in the process of pharmacy and medical benefit adoption.
Watch